# Astera Labs vs Arm: 2027 Tech Stock Pick

> Astera Labs' AI connectivity growth beats Arm's steady licensing for 2027 investors.
- Title: Astera Labs vs Arm: 2027 Tech Stock Pick · The Motley Fool
- Summary: Astera Labs' AI connectivity growth beats Arm's steady licensing for 2027 investors.
- Keywords: astera labs, arm, ai infrastructure, semiconductor stock, revenue growth, valuation metrics, tech stock buy, The Motley Fool
- Source: The Motley Fool — https://fool.com/coverage/better-buy/2026/11/14/astera-labs-vs-arm-which-technology-stock-is-a-better-buy-for-2027
- Author: Seena Hassouna
- Published: 2026-11-14T19:34:02+00:00
- Read time: 1 min
- Topics: astera labs, arm, ai infrastructure, semiconductor stock, revenue growth, valuation metrics, tech stock buy, finance, money
## Astera Labs' AI Connectivity Focus
Astera Labs delivers triple-digit revenue growth by providing essential connectivity solutions for artificial intelligence infrastructure.

> Astera Labs provides the essential connectivity hardware that links ai chips together
## Arm's Licensing Dominance
Arm maintains a dominant position in the global semiconductor ecosystem through its high-margin architecture licensing and royalty model.

> Arm operates a unique and highly profitable business model by licensing its compute architecture to the world's leading chipmakers
## Astera Labs Revenue Growth
In the 12 months ended sept 30 2026 revenue reached nearly $1.6 billion representing growth of approximately 115.2% compared to the prior twelve-month period.

> In its latest annual report astera labs noted that one end customer accounted for over 70% of revenue
## Arm Revenue Growth
In the 12 months ended sept 30 2026 revenue reached nearly $5.5 billion marking an increase of roughly 23.8% over the previous year.

> Arm earns its reputation as the steadier toll collector across phones pcs cars and data centers
## Astera Labs Financial Health
Astera labs has a current ratio of nearly 10.2x and debt-to-equity ratio of approximately 0.0x with free cash flow of nearly $281.8 million.

> The company has no debt relative to its shareholders equity
## Arm Financial Health
Arm has a current ratio of nearly 6.0x and debt-to-equity ratio of approximately 0.1x with free cash flow of nearly $979.0 million.

> The company has a conservative financial structure with plenty of liquidity to fund future research and development
## Risk Comparison
Astera faces revenue concentration with top three customers accounting for 86% of revenue and competition from broadcom marvell and credo technology group.

> The company must navigate an intensely competitive market against established giants like broadcom and marvell technology
## Valuation Metrics
Astera labs has a lower forward p/e of 53.1x and p/s ratio of 25.6x compared to arm's 89.2x and 38.9x.

> Astera looks more attractive on a relative basis with lower forward p/e and p/s ratio while delivering faster revenue growth
## 2027 Stock Recommendation
Astera labs is the better 2027 tech stock buy due to early ai infrastructure growth and lower valuation risks than arm.

> Astera labs is the one i'd own for 2027 and beyond because it looks like a company early in a very long runway
## Key takeaway

Astera Labs is the better 2027 tech stock buy due to faster AI infrastructure growth and lower valuation risks than Arm.